Reuters Health Report

Click to View in Browser 09/17/2014 First UK volunteer gets experimental GSK Ebola shot in trial LONDON (Reuters) - The first volunteer in a fast-tracked British safety trial of an experimental Ebola vaccine made by GlaxoSmithKline received the injection on Wednesday, trial organizers said. For Roche CEO, celebrating failure is key to success LONDON (Reuters) - Roche Chief Executive Severin Schwan likes to crack open the champagne with his drug research teams at the end of a big project - especially when they fail. Study shows downward trend in Sovaldi utilization (Reuters) - Over the last several months there has been a 'plateau and downward trend' in the use of Gilead Sciences Inc's controversial $1,000-a-pill hepatitis C treatment, Sovaldi, a CVS Health Corp analysis showed. Gilead's experimental drug fails mid-stage study (Reuters) - Gilead Sciences Inc said its experimental drug did not significantly improve how long patients with a type of pancreatic cancer lived without the disease worsening. Auxilium Pharma backs QLT deal, adopts poison pill after Endo's bid (Reuters) - Auxilium Pharmaceuticals Inc said it would not withdraw its offer to buy Canadian eye drug maker QLT Inc and adopted a poison pill, a day after receiving an unsolicited buyout offer from Endo International Plc. Food companies' U.S. calorie-cutting pledge could stall: researchers NEW YORK (Reuters) - A campaign by 16 of the world's largest food and beverage companies to dramatically cut the number of calories sold in the United States may have stalled after initial success, researchers reported on Wednesday. Citing security threat, Obama expands U.S. role fighting Ebola ATLANTA/MONROVIA (Reuters) - President Barack Obama on Tuesday called West Africa's deadly Ebola outbreak a looming threat to global security and announced a major expansion of the U.S. role in trying to halt its spread, including deployment of 3,000 troops to the region. India's Ranbaxy says U.S. authorities seek information on pricing data MUMBAI (Reuters) - Indian generic drugmaker Ranbaxy Laboratories Ltd said on Wednesday that federal authorities in the United States had sought details on how it reports pricing data for some products eligible for reimbursement under the Medicaid program. Urine test for cervical cancer virus offers alternative to smear LONDON (Reuters) - A simple urine test for the virus that causes cervical cancer could offer a less invasive and more acceptable alternative to the conventional cervical smear test, researchers said on Tuesday. Sanofi unveils heart disease partnership with MyoKardia PARIS (Reuters) - French drugmaker Sanofi announced on Wednesday a partnership with U.S.-based MyoKardia to develop therapies for patients with genetic heart diseases. Related Video Wildfires rage across bone-dry California Wireless charging technology comes to Formula-E racing The latest Reuters articles on M&A, IPOs, private equity, hedge funds and regulatory updates delivered to your inbox each day. Register Today   A daily digest of breaking business news, coverage of the US economy, major corporate news and the financial markets. Register Today   » MORE NEWSLETTERS

- 3 Times Square New York, NY 10036 USA © Copyright 2010 Thomson Reuters Ensure delivery of Reuters Newsmails, add mail@nl.reuters.com to your address book. Details Subscribe to other Reuters newsletters. Unsubscribe from this newsletter. Follow us on Twitter Friend us on Facebook Forward to a friend